Theravance Biopharma (NASDAQ:TBPH) Share Price Passes Above Fifty Day Moving Average - Time to Sell?

Key Points

• Theravance Biopharma's stock price has recently exceeded its 50-day moving average of $11.54, reaching a high of $14.27, and currently trading at $13.80.
• Multiple analysts have upgraded the stock's rating to "strong-buy", with target prices ranging from $24.00 to $25.00, contributing to an average price target of $21.33.
• Institutional investors hold a significant majority of Theravance Biopharma's shares, accounting for 99.10% of the company's ownership.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $11.54 and traded as high as $14.27. Theravance Biopharma shares last traded at $13.80, with a volume of 611,777 shares changing hands.

Analyst Ratings Changes

A number of brokerages have weighed in on TBPH. Wall Street Zen raised Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 16th. Jones Trading raised Theravance Biopharma to a "strong-buy" rating and set a $24.00 target price for the company in a research report on Tuesday, June 17th. BTIG Research lifted their price target on Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a report on Friday, June 27th. Finally, Zacks Research upgraded Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a report on Friday, August 15th. Two analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Strong Buy" and a consensus target price of $21.33.

Theravance Biopharma Stock Performance

The company has a 50 day moving average of $11.74 and a two-hundred day moving average of $10.25. The stock has a market capitalization of $703.53 million, a PE ratio of 58.21 and a beta of 0.01.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 10,000 shares of the business's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $11.39, for a total transaction of $113,900.00. Following the sale, the senior vice president owned 326,918 shares in the company, valued at approximately $3,723,596.02. The trade was a 2.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders sold 44,000 shares of company stock worth $491,800. 6.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Theravance Biopharma

Large investors have recently bought and sold shares of the business. Nuveen LLC acquired a new position in Theravance Biopharma during the first quarter worth $3,348,000. Newtyn Management LLC lifted its stake in Theravance Biopharma by 5.7% during the fourth quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company's stock worth $44,767,000 after purchasing an additional 258,337 shares in the last quarter. Jefferies Financial Group Inc. lifted its stake in Theravance Biopharma by 1,191.9% during the second quarter. Jefferies Financial Group Inc. now owns 276,887 shares of the biopharmaceutical company's stock worth $3,054,000 after purchasing an additional 255,455 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Theravance Biopharma by 121,993.7% in the first quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company's stock valued at $1,554,000 after acquiring an additional 174,451 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Theravance Biopharma by 20.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock valued at $5,211,000 after acquiring an additional 95,304 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company's stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.